BioCentury
ARTICLE | Company News

Mylan, Teva autoimmune news

September 7, 2015 7:00 AM UTC

The Patent Trials and Appeals Board (PTAB) of the U.S. Patent and Trademark Office instituted inter partes review (IPR) proceedings challenging two patents that cover Teva’s thrice-weekly formulation ...